PhII ICb With/Without Erbitux in MBC Pts
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Irinotecan + Carboplatin|DRUG: irinotecan + Carboplatin + erbitux
Sponsor: US Oncology Research
Collaborators: Bristol-Myers Squibb|Pfizer